Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma

Blood

Volumn 118, Issue 18, 2011, Pages 4808-4816

  Griffiths, Robert ^a,b   Mikhael, Joseph ^c   Gleeson, Michelle ^a   Danese, Mark ^a   Dreyling, Martin ^d  

^a Outcomes Insight Inc   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER STAGING; FEMALE; FOLLOW UP; HUMAN; MALE; MANTLE CELL LYMPHOMA; MEDICARE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL;

EID: 80855144802     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-04-348367     Document Type: Article

References (50)

1. Dreyling M, Hiddemann W, European MCL Network. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology Am Soc Hematol Educ Program. 2009:542-551.
2. Martin P, Chadburn A, Christos P, et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol. 2009;27(8):1209-1213.
3. Fernàndez V, Salamero O, Espinet B, et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res. 2010;70(4):1408-1418.
4. Hermine O, Hoster E,Walewski J, et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high doseARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses of CHOP plus rituximab followed by myeloablative radiochemotherapy andASCT in mantle cell lymphoma: results of the MCLYounger Trial of the European Mantle Cell Lymphoma Network (MCL net). Paper presented at: 52nd American Society of Hematology Annual Meeting and Exposition; December 4-7, 2010; Orlando, FL.
5. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-Bcell lymphoma. N Engl J Med. 2002;346:235-242. (Pubitemid 34438862)
6. Habermann T, Weller E, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006; 24(19):3121-3127. (Pubitemid 46638950)
7. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomized controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006;7:379-391.
8. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116(12):2040-2045.
9. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106: 3725-3732. (Pubitemid 41742196)
10. Herold M, Haas A, Srock S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group hematology and oncology study. J Clin Oncol. 2007;25(15):1986-1992. (Pubitemid 46972781)
11. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol. 2008;26:4579-4586.
12. Salles G, Mounier N, de Guibert S, et al. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood. 2008; 112:4824-4831.
13. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164-1174.
14. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2005;23(9):1984-1992. (Pubitemid 46211378)
15. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2007;99(9):706-714. (Pubitemid 47078732)
16. Forstpointner R, Dreyling M, Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104(10): 3064-3071. (Pubitemid 39517009)
17. Herold M, Pasold R, Srock S, et al. Results of a prospective randomised open label phase III study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell lymphoma (MCL) [abstract]. Blood. 2004;104(11 suppl 1):Abstract 584.
18. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced mantle cell lymphoma. J Clin Oncol. 2009;27(4):511-518.
19. National Cancer Institute. Surveillance, epidemiology, and end results. Data set and software. Available from http://seer.cancer.gov/seerstat/. Accessed January 17, 2011.
20. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329:987-994.
21. Solal-Céligny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265. (Pubitemid 39166497)
22. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111:558-565.
23. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF. Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002;40:IV-3-18.
24. National Cancer Institute. About the SEER Program. Available from: http://seer.cancer.gov/about/. Accessed August 27, 2010.
25. National Cancer Institute. SEER-Medicare: How the SEER & Medicare Data are Linked. Available from: http://healthservices.cancer. gov/seermedicare/overview/linked.html. Accessed August 27, 2010.
26. North American Association of Central Cancer Registries. Guidelines for ICD-O-3 Implementation. Available from: www.facs.org/cancer/coc/naaccr.pdf. Accessed February 24, 2011.
27. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care. 2002;40(8 suppl):IV-55-61.
28. National Cancer Institute. Procedure Codes for SEER-Medicare Analysis. Available from: http://healthservices.cancer.gov/seermedicare/considerations/ procedure-codes.html. Accessed December 7, 2010.
29. Practice Management Information Corporation. HCPCS. Los Angeles, CA: Practice Management Information Corporation; 2005.
30. Fritz A, Ries L, eds. SEER Program Code Manual. 3rd ed. Available from: http://seer. cancer.gov/manuals/codeman.pdf. Accessed October 5, 2010.
31. Young JL Jr., Roffers SD, Ries LAG, Fritz AG. SEER Summary Staging Manual - 2000 Codes and Coding Instructions. (National Institutes of Health publication number 01-4969). Available from: http://seer.cancer.gov/tools/ssm/ intro.pdf. Accessed January 4, 2011.
32. Practice Management Information Corporation. ICD-9-CM. 6th ed. Los Angeles, CA: Practice Management Information Corporation; 2005.
33. Danese MD, Griffiths RI, Gleeson M, et al. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia. Blood. 2011; 117(13):3505-3513.
34. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-655. (Pubitemid 13149996)
35. Davidoff AJ, Tang M, Seal B, Edelman MJ. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol. 2010;28(13):2191-2197.
36. Klabunde CN, Potosky AL, Legler JM, Warren JL. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000;53:1258-1267. (Pubitemid 32007842)
37. Klabunde CN, Legler JM, Warren JL, Baldwin L-M, Schrag D. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol. 2007;17:584-590. (Pubitemid 47096709)
38. National Cancer Institute. SEER-medicare: calculation of comorbidity weights. Available from: http://healthservices.cancer.gov/seermedicare/program/ comorbidity.html. Accessed August 27, 2010.
39. National Cancer Institute. Overview of the SEER Program. Available from: http://healthservices. cancer.gov/seermedicare/program/charlson.comorbidity. macro.txt. Accessed August 27, 2010.
40. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383. (Pubitemid 17055592)
41. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45:613-619.
42. Romano PS, Roos LL, Luft HS, Jollis JG, Doliszny K. A comparison of administrative versus clinical data: coronary artery bypass surgery as an example. Ischemic Heart Disease Patient Outcomes Research Team. J Clin Epidemiol. 1994;47:249-260. (Pubitemid 24109737)
43. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology Non-Hodgkin's Lymphomas V. 1.2010. Available from: http://www.nccn.org/professionals/physician-gls/f-guidelines.asp. Accessed January 4, 2011.
44. ResDAC. Research Data Assistance Center. CMS 301: Using SEER/Medicare Data for Research. ResDAC, May 15-16, 2008, Minneapolis, MN.
45. Earle CC, Nattinger AB, Potosky AL, et al. Identifying cancer relapse using SEER-Medicare data. Med Care. 2002;40(8 suppl):IV-75-81.
46. Stokes ME, Thompson D, Montoya EL, et al. Tenyear survival and cost following breast cancer recurrence: estimates from SEER-Medicare data. Value in Health. 2008;11:213-220. (Pubitemid 351473603)
47. Rubin DR. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
48. Griffiths R, Gleeson M, Reyes C, Knopf K, Danese M. Survival in elderly follicular lymphoma patients who receive frontline chemoimmunotherapy. Am J Hematol. 2010;85(12): 963-967.
49. Griffiths R, Gleeson M, Knopf K, Danese M. Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL). BMC Cancer. 2010;10:625- 639.
50. Giordano SH, Kuo Y-F, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS. Limits of observational data in determining outcomes from cancer therapy. Cancer. 2008;112:2456-2466.